MeSH term
Frequency | Condition_Probility | Case-Control Studies | 5 | 0.0 |
Humans | 227 | 0.0 |
Phosphoprotein Phosphatase/*metabolism | 8 | 9.0 |
Phosphorylation | 24 | 0.0 |
Animals | 69 | 0.0 |
Blood Glucose/analysis | 10 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Female | 91 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
Islets of Langerhans/*pathology | 2 | 25.0 |
Male | 88 | 0.0 |
Research Support, Non-U.S. Gov't | 107 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 33 | 0.0 |
Adult | 82 | 0.0 |
Aged | 27 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Middle Aged | 61 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
English Abstract | 36 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
Mutation | 5 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Transfection | 8 | 0.0 |
Adolescent | 29 | 0.0 |
Aging/*metabolism | 2 | 0.0 |
Arrestins/*metabolism | 2 | 28.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Time Factors | 17 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Heart Rate/physiology | 2 | 2.0 |
Prospective Studies | 5 | 0.0 |
Survival Analysis | 3 | 0.0 |
Pancreatic Polypeptide/*analysis | 3 | 33.0 |
Alzheimer Disease/*metabolism | 3 | 1.0 |
Amino Acid Sequence | 23 | 0.0 |
Blotting, Western | 9 | 0.0 |
Brain/*metabolism | 4 | 0.0 |
Molecular Sequence Data | 26 | 0.0 |
Molecular Weight | 3 | 0.0 |
Phosphates/analysis | 2 | 20.0 |
Phosphoserine/*metabolism | 2 | 7.0 |
Solubility | 3 | 0.0 |
Phosphoserine/metabolism | 3 | 3.0 |
Blood Pressure/physiology | 2 | 1.0 |
Posture/*physiology | 2 | 6.0 |
Child | 14 | 0.0 |
Comparative Study | 37 | 0.0 |
Exercise Test | 3 | 1.0 |
*Sex Characteristics | 2 | 1.0 |
Base Sequence | 9 | 0.0 |
DNA Primers | 2 | 0.0 |
Mice | 23 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
Diet | 2 | 0.0 |
Infant | 4 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Niacinamide/deficiency | 2 | 100.0 |
Nutrition Surveys | 2 | 9.0 |
Russia | 3 | 3.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 5 | 0.0 |
Glycogen Synthase Kinase 3 | 2 | 2.0 |
Hippocampus/*metabolism | 2 | 2.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
Okadaic Acid/pharmacology | 10 | 12.0 |
Phosphoprotein Phosphatase/*antagonists & inhibitors | 2 | 12.0 |
Up-Regulation | 2 | 0.0 |
*Apoptosis | 3 | 0.0 |
DNA Fragmentation/drug effects | 2 | 2.0 |
Enzyme Activation | 3 | 0.0 |
HL-60 Cells | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Phosphoprotein Phosphatase/metabolism | 4 | 5.0 |
Precipitin Tests | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Catalysis | 4 | 0.0 |
Cell Line | 14 | 0.0 |
Kinetics | 7 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Phosphoprotein Phosphatase/*antagonists & inhibitors/metabolism | 4 | 66.0 |
*Pyrans | 2 | 33.0 |
*Spiro Compounds | 2 | 25.0 |
Substrate Specificity | 3 | 0.0 |
Binding, Competitive | 3 | 0.0 |
Hamsters | 6 | 0.0 |
Ligands | 3 | 0.0 |
Protein Binding | 4 | 0.0 |
Rats | 27 | 0.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Cholecystokinin/blood | 2 | 3.0 |
Neurotensin/blood | 3 | 42.0 |
Pancreatic Polypeptide/blood | 19 | 32.0 |
Postprandial Period/physiology | 2 | 11.0 |
Biopsy | 3 | 0.0 |
Chronic Disease | 3 | 0.0 |
Gastrins/analysis | 2 | 15.0 |
Glucagon/analysis | 3 | 16.0 |
Insulin/analysis | 3 | 13.0 |
Pancreatic Polypeptide/analysis | 4 | 26.0 |
Polymorphism, Genetic | 2 | 0.0 |
Receptors, Estrogen/*genetics | 2 | 2.0 |
Blotting, Northern | 2 | 0.0 |
Phosphoprotein Phosphatase/*biosynthesis/chemistry | 2 | 100.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Phosphoprotein Phosphatase/antagonists & inhibitors/metabolism | 2 | 22.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Pancreatic Polypeptide/pharmacology | 2 | 20.0 |
*Photochemotherapy | 2 | 4.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Drug Administration Schedule | 3 | 0.0 |
Drug Synergism | 2 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Glaucoma, Open-Angle/*drug therapy/physiopathology | 2 | 100.0 |
Treatment Outcome | 4 | 0.0 |
Alleles | 4 | 0.0 |
3T3 Cells | 3 | 0.0 |
Apoptosis/*drug effects | 4 | 0.0 |
DNA Replication/*drug effects | 2 | 3.0 |
Genes, Reporter | 3 | 0.0 |
Guinea Pigs | 4 | 0.0 |
Nafenopin/pharmacology | 2 | 66.0 |
Oxidation-Reduction | 2 | 0.0 |
Peroxisome Proliferators/*pharmacology | 2 | 25.0 |
Rats, Inbred F344 | 2 | 0.0 |
Species Specificity | 6 | 0.0 |
Models, Molecular | 2 | 0.0 |
Cross-Sectional Studies | 4 | 0.0 |
Genotype | 3 | 0.0 |
Gene Expression | 3 | 0.0 |
Oxazoles/pharmacology | 6 | 15.0 |
Rats, Wistar | 4 | 0.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Peptide Fragments/*physiology | 2 | 7.0 |
Phosphoprotein Phosphatase/*chemistry | 2 | 33.0 |
Protein Conformation | 2 | 0.0 |
Coronary Angiography | 2 | 0.0 |
Cells, Cultured | 9 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Phosphoprotein Phosphatase/antagonists & inhibitors/*metabolism | 4 | 33.0 |
Phosphothreonine/metabolism | 3 | 7.0 |
S Phase | 3 | 0.0 |
In Vitro | 6 | 0.0 |
Pancreatic Polypeptide/*metabolism | 3 | 27.0 |
Catalytic Domain | 2 | 0.0 |
Manganese/*metabolism | 2 | 28.0 |
Vanadates/pharmacology | 2 | 1.0 |
Energy Metabolism | 2 | 1.0 |
*Nutrition | 4 | 10.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Autoradiography | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Cantharidin/pharmacology | 2 | 50.0 |
Umbilical Veins | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Gastrointestinal Hormones/*blood | 13 | 13.0 |
Statistics, Nonparametric | 2 | 0.0 |
Reference Values | 8 | 0.0 |
Neuropeptide Y/genetics/metabolism | 2 | 33.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Patch-Clamp Techniques | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Pancreatic Polypeptide/*physiology | 2 | 100.0 |
Sequence Alignment | 4 | 0.0 |
Hela Cells | 2 | 0.0 |
Phosphoprotein Phosphatase/antagonists & inhibitors/*physiology | 3 | 33.0 |
Calcium/metabolism | 2 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Histocytochemistry | 3 | 0.0 |
Cell Division | 3 | 0.0 |
Pancreatic Polypeptide/*pharmacology | 2 | 28.0 |
Flow Cytometry | 5 | 0.0 |
Isoenzymes/*analysis | 2 | 4.0 |
Macromolecular Substances | 2 | 0.0 |
Phosphoprotein Phosphatase/*analysis | 2 | 40.0 |
S Phase/physiology | 2 | 2.0 |
Exercise/*physiology | 3 | 0.0 |
Task Performance and Analysis | 2 | 6.0 |
ABO Blood-Group System/genetics | 6 | 14.0 |
Heterozygote Detection | 2 | 0.0 |
Phenotype | 6 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Transferrin/genetics | 2 | 4.0 |
Cell Differentiation | 2 | 0.0 |
Gestational Age | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Keratin/analysis | 2 | 0.0 |
Hydrocortisone/blood | 3 | 0.0 |
*Evolution | 3 | 1.0 |
Organ Specificity | 2 | 0.0 |
Rabbits | 3 | 0.0 |
Syndrome | 2 | 0.0 |
Dogs | 2 | 0.0 |
Bone Neoplasms/*enzymology/pathology | 3 | 75.0 |
Blood Pressure | 2 | 0.0 |
Prognosis | 3 | 0.0 |
Peptide YY | 7 | 6.0 |
Macaca mulatta | 3 | 0.0 |
Neuropeptide Y/*metabolism | 2 | 2.0 |
Biological Markers | 2 | 0.0 |
Pancreatic Polypeptide/metabolism | 5 | 23.0 |
Peptides/metabolism | 2 | 0.0 |
Receptors, Gastrointestinal Hormone/classification/*genetics/metabolism | 2 | 100.0 |
Receptors, Neuropeptide Y/classification/*genetics/metabolism | 2 | 100.0 |
Actins/metabolism | 3 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Cattle | 3 | 0.0 |
Ethers, Cyclic/pharmacology | 3 | 8.0 |
Okadaic Acid | 3 | 6.0 |
Insulin/blood | 15 | 2.0 |
Pancreatic Neoplasms/blood | 2 | 25.0 |
Pancreatic Polypeptide/*blood | 10 | 50.0 |
Microscopy, Electron | 4 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Chondrosarcoma/*enzymology/pathology | 2 | 100.0 |
Cell Cycle | 2 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Drug Evaluation | 3 | 1.0 |
Esophagus/*physiology | 2 | 40.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Gastrins/blood | 7 | 9.0 |
Somatostatin/blood | 5 | 20.0 |
Vasoactive Intestinal Peptide/blood | 10 | 24.0 |
Glucagon/metabolism | 2 | 7.0 |
Insulin/metabolism | 2 | 1.0 |
Radioimmunoassay | 4 | 0.0 |
Glucagon/blood | 11 | 11.0 |
Motilin/blood | 6 | 33.0 |
Pancreatic Hormones/blood | 2 | 50.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Erythrocytes/*chemistry | 2 | 5.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Protoporphyrins/*blood | 4 | 33.0 |
Cross Reactions | 2 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Laboratory Techniques and Procedures/standards | 2 | 25.0 |
Lead/blood | 2 | 15.0 |
Occupational Exposure | 2 | 2.0 |
Cell Line, Tumor | 3 | 0.0 |
Peptides/analysis | 2 | 2.0 |
Receptors, Neuropeptide Y | 2 | 6.0 |
Heterozygote | 3 | 0.0 |
Porphyrins/*blood | 2 | 40.0 |
Hormones/*blood | 5 | 3.0 |
Injections, Intravenous | 2 | 0.0 |
Cats | 2 | 0.0 |
USSR | 4 | 22.0 |
Appetite Regulation/*physiology | 2 | 14.0 |
*Digestive Physiology | 2 | 6.0 |
Pancreas/*secretion | 2 | 9.0 |
Infusions, Intravenous | 2 | 0.0 |
Pancreatic Polypeptide/blood/*secretion | 2 | 25.0 |
Epinephrine/blood | 2 | 1.0 |
Norepinephrine/blood | 2 | 1.0 |
Vitamins/*metabolism | 2 | 100.0 |
Blood Glucose/metabolism | 9 | 1.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Growth Hormone/blood | 2 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
*Food | 3 | 3.0 |
Gastric Inhibitory Polypeptide/blood | 10 | 26.0 |
Body Weight | 2 | 0.0 |
Pregnancy | 4 | 0.0 |
Secretin/blood | 2 | 20.0 |
Food | 2 | 1.0 |
Nutritional Status | 2 | 1.0 |
Peptides/*blood | 3 | 4.0 |
Substance P/blood | 2 | 20.0 |
Ascorbic Acid/*metabolism | 4 | 57.0 |
Niacinamide/*metabolism | 4 | 80.0 |
Pyridoxine/*metabolism | 3 | 75.0 |
Thiamine/*metabolism | 2 | 50.0 |
Sex Factors | 2 | 0.0 |
Gene Frequency | 5 | 0.0 |
*Genetics, Population | 5 | 1.0 |
Rh-Hr Blood-Group System/genetics | 4 | 14.0 |
*Eating | 2 | 3.0 |
Obesity/*blood/therapy | 3 | 75.0 |
Vasoactive Intestinal Peptide/*blood | 2 | 2.0 |
Eating | 2 | 1.0 |
Secretory Rate | 2 | 6.0 |
*Ethnic Groups | 2 | 1.0 |
Cross-Over Studies | 2 | 0.0 |
Glucose Tolerance Test | 3 | 0.0 |
Blood Proteins/genetics | 2 | 3.0 |
Protein Kinases/metabolism | 2 | 0.0 |
*Pregnancy | 2 | 1.0 |
Pregnancy in Diabetics/*blood | 2 | 5.0 |
Adipose Tissue/metabolism | 2 | 1.0 |
Body Composition | 2 | 0.0 |
C-Peptide/*blood | 2 | 5.0 |
Cholesterol/blood | 2 | 0.0 |
*Exertion | 2 | 1.0 |
Gastric Inhibitory Polypeptide/*blood | 2 | 3.0 |
Hyperinsulinism/blood | 2 | 18.0 |
Insulin/*blood | 2 | 1.0 |
Triglycerides/blood | 2 | 0.0 |
Gastrointestinal Hormones/*analysis | 3 | 10.0 |
*Chromosomes, Human, 21-22 and Y | 2 | 11.0 |
Karyotyping | 2 | 0.0 |
Pancreatic Hormones/*blood | 4 | 44.0 |
Enteroglucagon/blood | 2 | 28.0 |
Endorphins/analysis | 2 | 50.0 |
Hormones/*analysis | 2 | 66.0 |
Pyridoxine/metabolism | 2 | 100.0 |
Riboflavin/metabolism | 2 | 50.0 |
Thiamine/metabolism | 2 | 28.0 |
